ICH M10 — Bioanalytical Method Validation and Study Sample Analysis (2022)
概述 Overview
Document: ICH M10 Guideline — Bioanalytical Method Validation and Study Sample Analysis
Agency: ICH (International Council for Harmonisation)
Adopted: Step 4 — May 24, 2022
Status: Final; implemented by FDA, EMA, PMDA, Health Canada
Source: https://www.ich.org/page/multidisciplinary-guidelines
PDF: https://database.ich.org/sites/default/files/M10_Guideline_Step4_2022_0524.pdf
Q&As: https://database.ich.org/sites/default/files/ICH_M10_QAs_2022_1111.pdf
ICH M10 is the global harmonized standard for bioanalytical method validation. It supersedes both the FDA BMV 2018 guidance (for US) and the EMA BMV 2012 guideline (for EU). For ADC programs, it is the primary regulatory framework for validating TAb, cAb, free payload, and ADA assays.
核心要点 Key Points
1. Scope
M10 covers validation of two categories of bioanalytical methods:
- Chromatographic methods (LC-MS/MS, GC-MS) — primary platform for free payload and catabolites
- Ligand-binding assays (LBA) — primary platform for TAb and cAb; also used for ADA (addressed in a separate chapter)
What M10 does NOT cover:
- Biomarker method validation (separate FDA guidance exists)
- Immunogenicity (ADA) assays — covered in Section 7 of M10 and cross-referenced to agency-specific ADA guidances
2. Chromatographic Method Validation Parameters
| Parameter | Acceptance Criteria | Notes |
|---|---|---|
| Selectivity | No interference >20% at LLOQ; no suppression >25% | Test ≥6 individual matrix lots; include lipemic, hemolyzed, protein-bound |
| LLOQ | Accuracy: ±20%; Precision: ≤20% CV | Must be at/below minimum expected study concentration |
| Calibration range | ≥6 non-zero calibrators; r² ≥0.99 (1/x or 1/x² weighting common) | Must bracket expected study sample concentrations |
| Accuracy (within-run) | ≤15% deviation from nominal (±20% at LLOQ) | 3 QC levels (LQC, MQC, HQC) |
| Precision (within-run) | ≤15% CV (≤20% at LLOQ) | Minimum 5 replicates per QC level per run |
| Accuracy (between-run) | ≤15% (±20% at LLOQ) | ≥3 separate validation runs |
| Precision (between-run) | ≤15% CV (≤20% at LLOQ) | Combined across ≥3 runs |
| Matrix effect | IS-normalized ME: ≤15% CV | Test ≥6 individual matrix lots; post-column infusion or stable-label IS |
| Carryover | <20% of LLOQ; <5% of IS | Inject ULOQ sample followed by blank |
| Dilutional integrity | ≤15% accuracy/precision at each dilution factor tested | Minimum 5-fold and highest dilution expected in study |
| Stability | Bench-top (4 h min), F-T (≥3 cycles), long-term (≥study duration), processed | All at LQC and HQC; ≤15% deviation |
3. LBA Validation Parameters
LBA validation has distinct acceptance criteria reflecting higher biological variability:
| Parameter | Acceptance Criteria | ADC-Specific Note |
|---|---|---|
| Selectivity | ≤20% CV across ≥10 individual matrix lots | Include hemolyzed (1%), lipemic (TG >600 mg/dL), bilirubin-elevated lots |
| LLOQ | ±20% accuracy; ≤20% CV; S/N ≥10 | For ADC, LLOQ must cover expected concentrations in terminal PK sampling |
| ULOQ | Define upper limit of accurate quantitation | Hook effect must be assessed; ULOQ must have S/N confirmed |
| Calibration curve | ≥6 non-zero calibrators; 4PL (sigmoidal) or 5PL fit | Logistic regression commonly used |
| Accuracy | ±15% bias (±20% at LLOQ) across all QCs | 3 QC levels minimum |
| Precision | ≤15% CV (≤20% at LLOQ) | Separate intra- and inter-run precision runs |
| Hook effect | Demonstrate assay signal does not decrease at ULOQ or above | Assess at 3–5× above ULOQ minimum |
| Parallelism | Serial dilution of incurred sample parallel to calibration curve | Demonstrates same dose-response relationship; ≤30% slope difference acceptable |
| ISR | ≥67% of ISR samples within ±20% of original result | ≥10% of study samples (or 67 samples, whichever greater) |
| Stability | Same conditions as chromatographic | Reference standard stability in storage critical (often ≥12 months needed) |
4. Critical Reagents (Section Specific to LBA)
M10 introduces formal requirements for critical reagent management — directly relevant to ADC bioanalysis:
- Definition: Reagents whose performance significantly impacts assay results (anti-drug antibody, target antigen, reference standard)
- Requirement: Characterize each critical reagent lot before use; define acceptance criteria; perform bridging studies when lots change
- Reference standard characterization: Must demonstrate appropriate biological activity, purity, and stability; DAR characterization required for ADC reference standards used in cAb assays
- Documentation: Lot numbers, storage conditions, in-use stability, and bridging study results must be archived
5. Study Sample Analysis Requirements
These apply during bioanalysis of actual study samples (not just validation):
- QC samples: Include ≥3 QC levels with each analytical run; ≥67% of QC samples must pass acceptance criteria
- Calibration curve: Must bracket the majority of study samples; samples outside range must be diluted and re-assayed
- Re-injection reproducibility: If samples are re-injected (e.g., instrument failure), pre-validate re-injection reproducibility
- ISR: Mandatory for chromatographic and LBA methods in GCP studies; protocol specified before study start
6. Full Validation vs. Partial Validation vs. Cross-Validation
| Type | When Required | Minimum Requirements |
|---|---|---|
| Full validation | New method; GCP study; registrational trial | All parameters above |
| Partial validation | Minor change to validated method (e.g., new species, new concentration range, new anticoagulant) | Only parameters affected by the change |
| Cross-validation | Comparing two methods used in the same study (e.g., ELISA vs. hybrid LBA-MS for cAb) | Demonstrate ≤30% difference for ≥67% of cross-validated samples |
7. M10 vs. FDA BMV 2018 — Key Differences
| Parameter | M10 (2022) | FDA BMV (2018) |
|---|---|---|
| Regulatory scope | Global (FDA, EMA, PMDA, HC) | US only |
| LBA: number of matrix lots | ≥10 (for selectivity) | ≥6 individual lots |
| Parallelism | Explicitly required; defined criteria | Recommended but criteria less defined |
| Critical reagents | Formal section with specific requirements | Briefly mentioned |
| ISR | Defined %: ≥10% or 67 samples, ≥67% within ±20% LBA | Same %; similar criteria |
| Study sample analysis | Formal section integrated | Covered separately |
Practical implication for ADC programs: Programs that fully validated under FDA BMV 2018 may need partial re-validation or bridging to demonstrate M10 compliance for global submissions. FDA accepts both, but ICH M10 is preferred for new submissions after 2022.
常见问题和挑战，具体案例和解决方案
Challenge 1: Parallelism Failure for cAb Assay
Problem: When real study samples (incurred samples) are serially diluted, the dilution-response curve is not parallel to the calibration curve. This suggests that the antibody-linker-drug complex in study samples has a different immunoreactivity from the calibrator (reference standard) — possible if DAR of study samples differs from calibrator, or if catabolism created new forms.
M10 requirement: Parallelism assessment is mandatory; non-parallel samples must be investigated.
Solution:
- Characterize DAR of reference standard vs. DAR of study samples at comparable time points (using hybrid LBA-MS or HIC-HPLC)
- If DAR-mismatch is the cause: develop a DAR-matched calibrator or use a DAR-independent detection approach (e.g., anti-Fc detection for TAb)
- Report parallelism data in the study report with scientific justification for any deviations
Case: In early T-DM1 clinical studies, cAb ELISA calibrators had a lower average DAR (~3.0) than freshly dosed clinical ADC (~3.5). Serial dilution of early post-dose samples showed non-parallelism. Resolution: calibrator lot was re-characterized and a new lot with DAR matched to clinical drug was implemented.
Challenge 2: Hook Effect in High-Dose Cohorts
Problem: At dose escalation doses 3–5× above the clinical therapeutic dose, post-dose cAb or TAb concentrations may exceed ULOQ and enter the hook effect zone, giving falsely low readings.
M10 requirement: ULOQ must be defined with hook effect assessment; minimum dilution must be specified.
Solution:
- During validation, test concentrations at ULOQ, 3×, 5×, and 10× ULOQ to map the hook effect onset
- Define minimum required dilution (MRD) such that all expected maximum-dose Cmax samples are within the validated range after MRD
- For Phase 1 dose escalation where Cmax is unknown: implement a tiered dilution strategy (dilute all Cmax samples at 2×, 10×, 50× MRD)
Challenge 3: ISR Failures Due to Sample Instability
Problem: ISR failure (>33% of samples failing ±20% criteria) triggered by degradation of ADC in frozen samples that were re-thawed after 12+ months in storage.
M10 requirement: Long-term frozen stability must cover the actual study duration; if this stability cannot be confirmed before study end, risk must be managed.
Solution:
- Begin long-term stability assessment with validation (at study start); check at 3-, 6-, 12-month intervals
- If stability data lags the study duration, conduct a stability confirmation assay using incurred samples from early time points to verify
- If instability detected: investigate whether the instability is pre-analytical (occurred before storage) or in storage; identify the degradation product (by LC-MS) and determine if it represents actual in vivo degradation
相关条目 Related Entries
- FDA BMV 2018 — US predecessor; differences table
- FDA ADC ClinPharm 2024 — Analyte panel requirements that drive M10 scope
- FDA Immunogenicity 2019 — ADA assay framework (cross-referenced by M10 Section 7)
- AAPS ADC White Papers — Industry consensus predating M10; many recommendations now formalized in M10
- 04_bioanalysis_nonclinical — Non-clinical assay implementation
- 05_bioanalysis_clinical — Clinical assay validation requirements